Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Crews

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Bioorganic & Medicinal Chemistry Letters|August 28, 1999
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biologyN Sin, K B Kim, M Elofsson, et al.
Oncogene|September 17, 2008
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancerA Rodriguez-Gonzalez, K Cyrus, M Salcius, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 10, 2001
Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survivalM F Princiotta, U Schubert, W Chen, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|November 1, 1993
MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissuesB K Brott, A Alessandrini, D A Largaespada, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2000
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic dosesK Schwarz, R de Giuli, G Schmidtke, et al.
The Journal of Clinical Investigation|June 5, 2003
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitroI R Garrett, D Chen, G Gutierrez, et al.
Leukemia|July 1, 2017
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cellsB Sun, W Fiskus, Y Qian, et al.
Leukemia|January 3, 2017
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cellsD T Saenz, W Fiskus, Y Qian, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Bioorganic & Medicinal Chemistry Letters|August 28, 1999
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biologyN Sin, K B Kim, M Elofsson, et al.
Oncogene|September 17, 2008
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancerA Rodriguez-Gonzalez, K Cyrus, M Salcius, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 10, 2001
Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survivalM F Princiotta, U Schubert, W Chen, et al.
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|November 1, 1993
MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissuesB K Brott, A Alessandrini, D A Largaespada, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2000
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic dosesK Schwarz, R de Giuli, G Schmidtke, et al.
The Journal of Clinical Investigation|June 5, 2003
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitroI R Garrett, D Chen, G Gutierrez, et al.
Leukemia|July 1, 2017
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cellsB Sun, W Fiskus, Y Qian, et al.
Leukemia|January 3, 2017
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cellsD T Saenz, W Fiskus, Y Qian, et al.
Pageof 4